USPTO serial 79403954
ALCHEMAB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 18, 2025
- Examiner
- MEYERS, MORGAN LAURA
- Law office
- TMEG LAW OFFICE 104
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ALCHEMAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James M. Theo
James M. Theo Dinsmore & Shohl LLP222 West Adams StreetSuite 3400Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; Chemical preparations for medical and pharmaceutical purposes incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; antibodies for medical purposes; diagnostic preparations involving the testing and identification of antibodies for medical purposes; diagnostic preparations involving the testing of antibodies for medical purposes; diagnostic preparations involving the identification of antibodies for medical purposes. | ACTIVE | — |
| 009 | Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology. | ACTIVE | — |
| 042 | Research and development services in the field of antibodies and antibody technology; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery services in the nature of drug discovery services; development and testing of computing methods, algorithms and software for the testing and identification of antibodies; development and testing of computing methods, algorithms and software in the field of antibody technology; development and testing of computing methods, algorithms and software for use in or relating to the development of pharmaceutical preparations incorporating antibodies and antibody technology; information, advisory and consultancy services in relation to all of the aforesaid. | ACTIVE | — |
| 044 | Medical diagnostic services involving the testing of antibodies for medical purposes; medical diagnostic services involving the identification of antibodies for medical purposes; medical testing, analysis and diagnostic services in the field of antibodies; information, advisory and consultancy services in relation to all of the aforesaid. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alchemab Therapeutics Ltd
- Other trademarks owned by Alchemab Therapeutics Ltd
- Other trademarks owned by Alchemab Therapeutics Ltd
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ALCHEMAB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 4, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 4, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 14, 2026 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Mar 23, 2026 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Mar 9, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 19, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 18, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 4, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 4, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 9, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Nov 18, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 18, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 30, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 30, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 24, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 28, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 28, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 28, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 28, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 28, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 6, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 6, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 6, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 4, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 4, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 16, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 15, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 28, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 9, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 5, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |